查看“EGFR 激酶结构域突变”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>EGFR 激酶结构域突变</strong>（EGFR Kinase Domain Mutations）是指表皮生长因子受体（<strong>[[EGFR]]</strong>）基因在第 18 至 21 号<strong>[[外显子]]</strong>（Exons）区域发生的体细胞突变。这些突变会导致受体酪氨酸激酶（RTK）在没有配体结合的情况下持续活化，驱动肿瘤细胞的增殖和存活。在亚裔非小细胞肺癌（NSCLC）患者中，其发生率高达 40%-50%。根据对靶向药物的反应，可分为<strong>敏感突变</strong>（如 <strong>[[外显子19缺失]]</strong>、<strong>[[L858R]]</strong>）和<strong>耐药突变</strong>（如 <strong>[[T790M]]</strong>、<strong>[[C797S]]</strong>）。这些突变位点直接决定了临床是选择一代药物（如<strong>[[吉非替尼]]</strong>）还是三代药物（如<strong>[[奥希替尼]]</strong>）。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">EGFR Mutations</div>
            <div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Targetable Driver Mutations (点击展开)</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 25px; text-align: center; background-color: #f8fafc;">
                <div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
                    [Image:EGFR_mutation_types_distribution_chart.png]
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">肺腺癌的“黄金突变”</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">涉及基因</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[EGFR]]</strong> (erbB1)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">关键区域</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">外显子 18, 19, 20, 21</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">经典敏感突变</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #166534;"><strong>[[19del]]</strong>, <strong>[[L858R]]</strong><br>(占 85-90%)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">一代耐药突变</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>[[T790M]]</strong> (守门员)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">三代耐药突变</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>[[C797S]]</strong> (破坏共价键)</td>
                </tr>
                 <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">对应药物</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #166534;"><strong>[[EGFR-TKI]]</strong> (如奥希替尼)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">检测方法</th>
                    <td style="padding: 6px 12px; color: #0f172a;">ARMS-PCR, <strong>[[NGS]]</strong></td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">突变全景：从敏感走向耐药</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        EGFR 突变主要集中在编码 ATP 结合口袋的四个外显子中。不同的突变类型决定了 TKI 药物能不能“卡”进这个口袋。
    </p>

    <div style="overflow-x: auto; margin: 30px auto; max-width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: center;">
            <tr style="background-color: #eff6ff; color: #1e40af;">
                <th style="padding: 12px; border: 1px solid #cbd5e1; border-bottom: 2px solid #60a5fa; width: 15%;">外显子</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; border-bottom: 2px solid #60a5fa; width: 25%;">突变名称</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; border-bottom: 2px solid #60a5fa; width: 25%;">类型</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; border-bottom: 2px solid #60a5fa; width: 35%;">药物敏感性</th>
            </tr>
            <tr style="background-color: #f8fafc; font-weight: bold; text-align: left;">
                <td colspan="4" style="padding: 8px 12px; border: 1px solid #cbd5e1; color: #64748b;">I. 经典敏感突变 (Sensitizing)</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">Exon 19</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; color: #166534;"><strong>[[19del]]</strong></td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">缺失突变</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #dcfce7; color: #166534;">一代/二代/三代 <strong>均敏感</strong><br>(疗效优于 L858R)</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">Exon 21</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; color: #166534;"><strong>[[L858R]]</strong></td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">点突变</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #dcfce7; color: #166534;">一代/二代/三代 <strong>均敏感</strong></td>
            </tr>
            <tr style="background-color: #f8fafc; font-weight: bold; text-align: left;">
                <td colspan="4" style="padding: 8px 12px; border: 1px solid #cbd5e1; color: #64748b;">II. 获得性耐药突变 (Acquired Resistance)</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">Exon 20</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; color: #b91c1c;"><strong>[[T790M]]</strong></td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">守门员突变</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">
                    <span style="color: #b91c1c;">一代/二代耐药</span><br>
                    <span style="color: #166534;">三代(奥希替尼) <strong>敏感</strong></span>
                </td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">Exon 20</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; color: #b91c1c;"><strong>[[C797S]]</strong></td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">结合位点突变</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; background-color: #fee2e2; color: #b91c1c;">
                    <strong>三代耐药</strong><br>(需探索四代药或联合治疗)
                </td>
            </tr>
            <tr style="background-color: #f8fafc; font-weight: bold; text-align: left;">
                <td colspan="4" style="padding: 8px 12px; border: 1px solid #cbd5e1; color: #64748b;">III. 罕见突变 (Uncommon)</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">Exon 20</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>[[20ins]]</strong></td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">插入突变</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">
                    <span style="color: #b91c1c;">传统 TKI 耐药</span><br>
                    需用 <strong>[[埃万妥单抗]]</strong> / 莫博赛替尼
                </td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">Exon 18</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">G719X</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">点突变</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">对 <strong>[[阿法替尼]]</strong> (二代) 敏感</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心耐药机制解析</h2>
    <div style="background-color: #fff5f5; border-left: 5px solid #e11d48; padding: 15px 20px; margin: 20px 0; border-radius: 4px;">
        <h3 style="margin-top: 0; color: #be123c; font-size: 1.1em;">1. T790M：一代药的克星</h3>
        <p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;">
            T790M（苏氨酸→甲硫氨酸）位于 ATP 结合口袋的“大门”处，被称为<strong>[[守门员突变]]</strong>。
            <br>• <strong>空间位阻：</strong> 突变后引入的甲硫氨酸侧链较大，阻碍了一代 TKI（如吉非替尼）的结合。
            <br>• <strong>ATP亲和力增加：</strong> 突变使 EGFR 与 ATP 的亲和力恢复到接近野生型水平，药物竞争不过 ATP。
            <br>• <strong>对策：</strong> 第三代药物<strong>[[奥希替尼]]</strong>设计独特，能绕过位阻并不可逆结合。
        </p>
    </div>
    [Image:EGFR_T790M_mechanism_steric_hindrance.png]

    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>2. C797S：三代药的终结者</strong>
            <br>第三代 TKI（如奥希替尼）的关键机制是与 EGFR 第 797 位的<strong>半胱氨酸</strong>（Cys797）形成<strong>共价键</strong>。
            <br>• <strong>机制：</strong> 当 C797 突变为<strong>丝氨酸</strong>（Ser, S）后，共价键无法形成，奥希替尼结合极不稳定，导致耐药。
            <br>• <strong>对策：</strong> 若 C797S 与 T790M 位于不同等位基因（反式，trans），联合一代药可能有效；若位于同一等位基因（顺式，cis），目前无特效药，需化疗或 ADC。</li>
        <li style="margin-bottom: 12px;"><strong>3. 外显子 20 插入 ([[Exon 20ins]])：</strong>
            <br>曾是“难治性突变”。由于其结构改变不影响 ATP 结合口袋的大小，但限制了 TKI 的进入。目前已有<strong>[[双特异性抗体]]</strong>（埃万妥单抗）突破了这一瓶颈。</li>
    </ul>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Mok TS, et al. (2009).</strong> <em>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.</em> <strong>[[New England Journal of Medicine]]</strong>.<br>
            <span style="color: #475569;">[IPASS研究]：划时代的临床试验，首次证实了只有携带 EGFR 突变的患者才能从 TKI 治疗中获益，确立了“先检测，后治疗”的原则。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Soria JC, et al. (2018).</strong> <em>Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.</em> <strong>[[New England Journal of Medicine]]</strong>.<br>
            <span style="color: #475569;">[FLAURA研究]：确立了奥希替尼作为 EGFR 敏感突变一线治疗的金标准地位，显示其PFS和OS均优于一代药物。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [3] <strong>Thress KS, et al. (2015).</strong> <em>Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring T790M.</em> <strong>[[Nature Medicine]]</strong>.<br>
            <span style="color: #475569;">[耐药机制]：首次报道了 C797S 突变是导致奥希替尼耐药的主要机制，揭示了共价结合位点的重要性。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            EGFR 突变 · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">敏感突变</td>
                <td style="padding: 10px 15px; color: #334155;"><strong>[[19del]]</strong> (黄金缺失) • <strong>[[L858R]]</strong> (点突变)</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">耐药机制</td>
                <td style="padding: 10px 15px; color: #334155;"><strong>[[T790M]]</strong> (需奥希替尼) • <strong>[[C797S]]</strong> (目前无药) • MET扩增</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">罕见突变</td>
                <td style="padding: 10px 15px; color: #334155;"><strong>[[20ins]]</strong> (需埃万妥单抗) • G719X • S768I • L861Q</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗药物</td>
                <td style="padding: 10px 15px; color: #334155;">[[吉非替尼]] • [[厄洛替尼]] • [[阿法替尼]] • <strong>[[奥希替尼]]</strong></td>
            </tr>
        </table>
    </div>

</div>